Wilson Disease (WD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Wilson Disease (WD) is an inherited disorder of copper metabolism. The disease is caused by homozygous or compounds heterozygous mutations (the presence of two different mutant alleles) in ATP7B, which encodes transmembrane copper-transporting ATPase 2 (widely known as ATP7B), which mediates the excretion of copper into bile and delivers copper for the functional synthesis of ceruloplasmin (the major copper-transporting protein in the blood) diagnostic methods, ideal treatment regimens, efficacy evaluation standards and prognostic indicators for NPC. The liver is the site of metabolism for dietary copper; in WD, defective ATP7B function leads to copper overload in hepatocytes, which is associated with liver pathology.

·       Wilson disease (WD) prevalence ranges between 31 to 37 cases per 1,00,000 individuals in EU countries, 48 to 59 cases in the USA, and 33 cases per 1,000,000 individuals in Japan.

·       The global prevalence of WD was estimated to range between 1/30,000 to 1/10,000 individuals in non-isolated populations, with a mutation carrier frequency.

Thelansis’s “Wilson Disease (WD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wilson Disease (WD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Wilson Disease (WD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Wilson Disease (WD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Wilson Disease (WD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033